Neurotrope BioScience, Inc. (NASDAQ: NTRP) is a clinical-stage biopharmaceutical company headquartered in New York, NY, focused on developing novel therapies for Alzheimer's disease (AD) and other neurodegenerative disorders. The company is known for its development of bryostatin, a protein kinase C (PKC) modulator, as a potential treatment for Alzheimer's disease that aims to promote synaptic repair and neuroprotection[1].
| Attribute | Value |
|---|---|
| Founded | 2012 |
| Headquarters | New York, NY, USA |
| Stock Exchange | NASDAQ |
| Ticker | NTRP |
| IPO | 2014 |
| Focus | Alzheimer's disease, neurodegeneration |
Neurotrope was founded in 2012 with a focus on developing PKC-targeted therapies for neurological disorders. The company went public in 2014 on NASDAQ[1:1].
Key milestones:
Neurotrope's platform centers on protein kinase C (PKC) epsilon (PKCε) activation[2]:
Bryostatin is a macrocyclic lactone:
| Attribute | Details |
|---|---|
| Indication | Alzheimer's Disease |
| Mechanism | PKC epsilon activator |
| Stage | Phase 2 |
| Route | Intravenous infusion |
| Status | Clinical development |
Potential Benefits:
| Program | Indication | Stage |
|---|---|---|
| PKC modulators | Various CNS disorders | Preclinical |
| Novel analogs | AD, PD | Discovery |
Neurotrope has conducted multiple Phase 2 clinical trials evaluating bryostatin in Alzheimer's disease patients[2:1]:
Trial Design:
Challenges:
Bryostatin's potential benefits in AD include[2:2]:
Protein kinase C is essential for memory formation:
Animal studies show bryostatin:
Neurotrope competes in the AD therapeutic space:
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| Biogen/Lecanemab | Amyloid clearance | Antibody | Approved |
| Eli Lilly | Donanemab | Amyloid clearance | Approved |
| Roche | Gantenerumab | Amyloid clearance | Phase 3 |
| Neurotrope | Bryostatin | PKC activator | Phase 2 |
| Cortexyme | COR388 | Gingipain inhibitor | Phase 2/3 |
Administration: IV infusions vs. oral drugs
Competition: Successful amyloid-targeting therapies
Efficacy: Demonstrating clinical benefit
Manufacturing: Complex bryostatin synthesis
Neurotrope BioScience, Inc. Corporate information and pipeline. ↩︎ ↩︎
Alkon DL, Sun MK, Nelson TJ. PKC signaling deficits in Alzheimer's disease and therapeutic interventions. 2007. ↩︎ ↩︎ ↩︎